QuidelOrtho Corp QDEL
Biotechnology: In Vitro & In Vivo Diagnostic Substances · data as of November 13, 2026
QuidelOrtho Corp (QDEL) is a healthcare company listed in the US with a market value of about $737M. In the twelve months to September 27, 2026 it had revenue of $2.6B and net income of -$369M, a net margin of -14.2%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 10% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 54% below the current price.
About QuidelOrtho
QuidelOrtho is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances. Revenue went from $1.7B in 2020 to $2.7B in 2025, growth of about 10.4% a year. It was profitable in 3 of the last 6 years in our data. Its share count rose by 18% over three years (dilution for shareholders). It spends 7% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.6B | $2.7B | $2.8B | $3.0B | $3.3B | $1.7B | $1.7B |
| Net income | -$369M | -$1.1B | -$2.1B | -$10M | $549M | $704M | $810M |
| Free cash flow | -$117M | -$83M | -$112M | $71M | $744M | $513M | $565M |
| EPS (diluted) | $-5.39 | $-16.69 | $-30.54 | $-0.15 | $9.56 | $16.43 | $18.60 |
| Net margin | -14.2% | -41.4% | -73.7% | -0.3% | 16.8% | 41.5% | 48.8% |
| ROIC | — | -15.1% | -33.3% | 1.4% | 8.1% | 34.2% | 62.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $15.00, 40% above the current price; targets range from $12.00 to $20.00; the consensus rating is “Hold”; expected EPS is $0.67 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is QuidelOrtho stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 54% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does QuidelOrtho pay a dividend?
Not currently.
Is QuidelOrtho a good stock to buy?
We do not give buy or sell advice. QuidelOrtho scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.